Results 11 to 20 of about 63,359 (335)

IDH1/IDH2 Inhibition in Acute Myeloid Leukemia [PDF]

Frontiers in Oncology, 2021
Recently, the discovery of biological and clinical properties of mutated isoforms 1 and 2 mutations of isocitrate dehydrogenases (IDH) 1 and 2, affecting approximately 20% of patients with acute myeloid leukemia (AML), lead to the development of an ...
C. Cerchione, A. Romano, N. Daver, C. Dinardo, E. Jabbour, M. Konopleva, F. Ravandi-Kashani, T. Kadia, M. Martelli, A. Isidori, G. Martinelli, H. Kantarjian   +11 more
semanticscholar   +6 more sources

Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198

Cancer Research, 2015
Abstract Isocitrate dehydrogenase 1 (IDH1) is mutated in various types of human cancer to IDH1R132H, a structural alteration that leads to catalysis of α-ketoglutarate to the oncometabolite D-2-hydroxyglutarate. In this study, we present evidence that small-molecule inhibitors of IDH1R132H that are being developed for cancer therapy may ...
Remco J. Molenaar, Dennis Botman, Myrthe A J Smits, Vashendriya V.V. Hira, Sanne A. M. van Lith, Jan Stap, Peter Henneman, Mohammed Khurshed, Krissie Lenting, Adri N. Mul, Dionysia Dimitrakopoulou, Cornelis M. van Drunen, Ron A. Hoebe, Tomas Radivoyevitch, Johanna W. Wilmink, Jaroslaw P. Maciejewski, W. Peter Vandertop, William P. J. Leenders, Fonnet E. Bleeker, Cornelis J.F. Van Noorden   +19 more
openalex   +6 more sources

Wild-Type IDH1 and Mutant IDH1 Opposingly Regulate Podoplanin Expression in Glioma

Translational Oncology, 2020
Isocitrate dehydrogenase (IDH) mutations occur frequently in lower-grade gliomas, which result in genome-wide epigenetic alterations. The wild-type IDH1 is reported to participate in lipid biosynthesis and amino acid metabolism, but its role in ...
Chao Sun, Liming Xiao, Yuanlin Zhao, Jiankuan Shi, Yuan Yuan, Yu Gu, Feng Zhang, Xing Gao, Ying Yang, Risheng Yang, Junhui Qin, Jin Zhang, Chao Wang, Yingmei Wang, Zhe Wang, Peizhen Hu, Ting Chang, Liang Wang, Gang Wang, Huangtao Chen, Zhuyi Li, Jing Ye   +21 more
doaj   +3 more sources

Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations [PDF]

Acta Neuropathologica, 2021
AbstractSomatic mutations in the isocitrate dehydrogenase genesIDH1andIDH2occur at high frequency in several tumour types. Even though these mutations are confined to distinct hotspots, we show that gliomas are the only tumour type with an exceptionally high percentage of IDH1R132Hmutations.
Jan Oosting, Filip de Vos, Michael A. Vogelbaum, C Mircea S Tesileanu, Jaap C. Reijneveld, Martin J B Taphoorn, Thierry Gorlia, Robert B. Jenkins, Sara Erridge, Wolfgang Wick, Hendrikus J. Dubbink, Elizabeth Lim, Johan M. Kros, Paul Clement, Lorenzo Boggiani, Matthew E. Griffin, Jean Francais Baurain, Anna K. Nowak, Anna K. Nowak, Anna K. Nowak, Wies Vallentgoed, Martin J. van den Bent, Francesca Caparrotti, Anja Gijtenbeek, Pim J. French, Thierry Lesimple, Olivier Chinot, Michael Weller, Iris de Heer, Judith V.M.G. Bovée, Vassilis Golfinopoulos, Alba A. Brandes, Roelien H. Enting, Roberta Rudà, Sanjeev Gill, Paul Mulholland, Leland Rogers, Sanne Venneker, Kenneth Aldape, Marc Sanson, Pieter Wesseling, Susan Clenton, Warren P. Mason, Maurice de Wit, Youri Hoogstrate, Catherine McBain, Helen Wheeler, Walter Taal, Brigitta G. Baumert   +48 more
openaire   +15 more sources

Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia [PDF]

Annals of Hematology, 2020
Patients with newly diagnosed chronic phase chronic myeloid leukemia (CP CML) can be effectively treated with tyrosine kinase inhibitors (TKIs) and achieve a lifespan similar to the general population. The success of TKIs, however, requires long-term and sometimes lifelong treatment; thus, patient-assessed health-related quality of life (HRQoL) has ...
Gupta, Charu, Kaulfuss, Stefan, Görlich, Kerstin, Othman, Basem, Chaturvedi, Anuhar, Heuser, Michael   +5 more
openaire   +4 more sources

Characterization of the human IDH1 gene promoter

AIMS Molecular Science, 2023
In cancer, the production of ATP depends mainly on glycolysis, usually accompanied by the dysfunction of the tricarboxylic acid (TCA) cycle and oxidative phosphorylation (OXPHOS).
Yutaka Takihara, Ryuji Otani , Takuro Ishii, Shunsuke Takaoka, Yuki Nakano , Kaori Inoue, Steven Larsen, Yoko Ogino , Masashi Asai , Sei-ichi Tanuma , Fumiaki Uchiumi   +10 more
doaj   +1 more source

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.

New England Journal of Medicine, 2023
BACKGROUND Isocitrate dehydrogenase (IDH)-mutant grade 2 gliomas are malignant brain tumors that cause considerable disability and premature death.
I. Mellinghoff, M. J. van den Bent, D. Blumenthal, M. Touat, K. Peters, Jennifer L. Clarke, Joe S. Mendez, S. Yust-Katz, L. Welsh, W. Mason, F. Ducray, Y. Umemura, B. Nabors, M. Holdhoff, A. Hottinger, Yoshiki Arakawa, J. Sepúlveda, W. Wick, R. Soffietti, J. Perry, P. Giglio, M. I. de la Fuente, E. Maher, S. Schoenfeld, Dan Zhao, S. Pandya, L. Steelman, Islam Hassan, P. Wen, T. Cloughesy   +29 more
semanticscholar   +1 more source

Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial

Nature Network Boston, 2023
Vorasidenib and ivosidenib inhibit mutant forms of isocitrate dehydrogenase (mIDH) and have shown preliminary clinical activity against m IDH glioma.
I. Mellinghoff, Min Lu, P. Wen, Jennie W. Taylor, E. Maher, I. Arrillaga-Romany, K. Peters, B. Ellingson, M. Rosenblum, Saewon Chun, K. Le, A. Tassinari, S. Choe, Y. Toubouti, S. Schoenfeld, S. Pandya, Islam Hassan, L. Steelman, Jennifer L. Clarke, T. Cloughesy   +19 more
semanticscholar   +1 more source

Gene of the month:IDH1 [PDF]

Journal of Clinical Pathology, 2020
Isocitrate dehydrogenase 1(IDH1) encodes a protein which catalyses the oxidative decarboxylation of isocitrate to α-ketoglutarate. Mutant IDH1 favours the production of 2-hydroxyglutarate, an oncometabolite with multiple downstream effects which promote tumourigenesis.IDH1mutations have been described in a number of neoplasms most notably low-grade ...
Cassandra Bruce-Brand, Dhirendra Govender   +1 more
openaire   +3 more sources

Correlation of IDH1, p53 and Ki-67 immunoexpression levels with morphological, clinical prognostic parameters and preoperative/postoperative radiological findings and response to treatment in high-grade glial tumor case

Medicine Science, 2023
In this study, we aimed to investigate the prognostic factors affecting survival in adult patients with high-grade glial tumors. The retrospective study included 79 consecutive patients who were referred to our clinic for adjuvant radiotherapy ...
Murtaza Parvizi, Ulkun Unlu Unsal, Olcay Ak Nalbant, Derya Demir, Murat Akyol, Aydin Isisag   +5 more
doaj   +1 more source